Ruthigen /Pulmatrix merger closed on June 15, 2015 , enabling Oculus' sale of Ruthigen shares to close on or before June 18, 2015 Sale provides non-dilutive funding to support sales growth of dermatology products via Oculus' direct sales force PETALUMA, Calif.
Total revenue increased 37% to $4 million from $2.9 million in the same period last year; up 25% from the quarter ending December 31, 2014 Cash as of March 31, 2015 of $6.1 million and debt free Upon completion of Ruthigen merger, Oculus will receive an additional $4.5 million from the sale of
PETALUMA, Calif. , June 8, 2015 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced that it has received a new 510(k)
PETALUMA, Calif. , May 28, 2015 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), today announced that the financial results for its fiscal fourth quarter 2015, ended March 31, 2015 , will be released after the U.S. markets close on June 11, 2015 .
Ten North American distributors have added MicrocynAH® animal healthcare products to their product portfolios since launch in February 2015 Antibiotic-free MicrocynAH® helps create an optimal wound healing environment without the use of antibiotics, better enabling farmers and ranchers to support